ovarian cancer
Oncology · 2013–2025
18decisions
5medicines
15carried consumer input
100individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mirvetuximab soravtansine Treatment of patients with platinum-resistant high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least one prior… | Nov 2025 | Deferred | 1 individuals Rare Cancers Australia · Ovarian Cancer Australia · Inherited Cancers Australia · Medical Oncology Group |
| bevacizumab Multiple cancer indications: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small… | Mar 2024 | Recommended | 1 individuals Medical Oncology Group |
| niraparib Maintenance therapy in patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer that is homologous recombination… | Jul 2023 | Deferred | input received Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| olaparib Maintenance therapy in patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer that is HRD positive and BRCA… | Jul 2023 | Deferred | input received Ovarian Cancer Australia · Medical Oncology Group |
| olaparib Maintenance therapy in combination with bevacizumab for patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer… | Jul 2022 | Not recommended | input received Ovarian Cancer Australia · Medical Oncology Group |
| niraparib Maintenance therapy for newly diagnosed advanced (stage III-IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are… | Mar 2022 | Recommended with restriction | 55 individuals Ovarian Cancer Australia · Medical Oncology Group |
| niraparib Newly diagnosed advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (HGEOC), who are in response to platinum-based… | Jul 2021 | Not recommended | input received Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| niraparib Platinum-sensitive relapsed, high-grade serous ovarian, fallopian tube or primary peritoneal cancer (HGSOC) in response to platinum-based chemotherapy. | Mar 2021 | Not recommended | 14 individuals Ovarian Cancer Research Foundation · Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| olaparib Maintenance treatment of patients with newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube and primary peritoneal cancer… | Jul 2020 | Recommended with restriction | input received Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| topotecan Treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent therapy, small cell lung carcinoma after failure of first-line… | Jul 2020 | Recommended | input received Lung Foundation Australia · Medical Oncology Group |
| olaparib Maintenance treatment of platinum-sensitive relapsed ovarian, fallopian tube and primary peritoneal cancer in patients with somatic BRCA1/2 mutations (in… | Mar 2020 | Recommended with restriction | 1 individuals |
| olaparib Maintenance treatment of adult patients with advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer with… | Nov 2019 | Not recommended | input received Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| olaparib Maintenance treatment of women with germline BRCA1 or BRCA2 gene mutation (gBRCAm) and platinum-sensitive relapsed high-grade serous ovarian, fallopian tube or… | Mar 2018 | Recommended with restriction | unclear |
| olaparib Maintenance treatment of women with germline BRCA1/BRCA2 mutation (class 4 or 5) platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal… | Jul 2016 | Not recommended | input received |
| olaparib Maintenance treatment of women with BRCA1 or BRCA2 gene mutation and platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary… | Mar 2016 | Deferred | 28 individuals Medical Oncology Group · Rare Cancers Australia · Ovarian Cancer Australia |
| olaparib Maintenance treatment of women with germline BRCA1/BRCA2 mutation (class 4 or 5) with platinum-sensitive relapsed high grade serous ovarian cancer, fallopian… | Nov 2016 | Recommended with restriction | unclear |
| bevacizumab First-line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO stages IIIB, IIIC, or IV) in combination with… | Mar 2014 | Not recommended | input received Medical Oncology Group |
| bevacizumab First-line treatment in combination with chemotherapy of patients with previously untreated advanced epithelial ovarian, fallopian tube or primary peritoneal… | Nov 2013 | Recommended | no section in document |
Who spoke
Medical Oncology Group · Ovarian Cancer Australia · Rare Cancers Australia · Inherited Cancers Australia · Ovarian Cancer Research Foundation · Lung Foundation Australia
What the PBS pays
$114M in government benefit over 2024–25, across 91,973 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| olaparib | $60.9M |
| bevacizumab | $49.4M |
| niraparib | $3.3M |
| topotecan | $0.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 14 technologies for this condition, recommending 10 and declining 2. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| mirvetuximab soravtansineMirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer | TA1169 | recommended restricted | 2026-06 |
| niraparibNiraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1129 | recommended restricted | 2026-02 |
| rucaparibRucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | recommended restricted | 2025-04 |
| rucaparibRucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | recommended restricted | 2024-09 |
| olaparibOlaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | recommended restricted | 2024-03 |
| olaparibOlaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | recommended | 2024-01 |
| olaparibOlaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | recommended restricted | 2023-07 |
| niraparibNiraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | recommended restricted | 2022-04 |
| bevacizumabBevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | terminated | 2019-02 |
| topotecan pegylated liposomal doxorubicin hydrochloride paclitaxel trabectedin and gemcitabineTopotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | recommended | 2016-04 |
| bevacizumabBevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | terminated | 2015-08 |
| bevacizumabBevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | not recommended | 2013-05 |
Showing the 12 most recent of 14.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| cisplatinCISPLATIN ACCORD cisplatin 10 mg/10 mL concentrated injection vial | 1994 | 10 |
| epirubicinEPIRUBICIN ACCORD epirubicin hydrochloride 10mg/5mL concentrated injec | 1992 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 15 of 17 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.